Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The effects of magnesium on cardiac arrhythmias caused by digitalis.

Clinical science·2014

Same author

The action of magnesium on the heart.

British heart journal·2010

Same author

Adder Bite.

British medical journal·2010

Same author

Predictability of physiological testing and the role of maturation in talent identification for adolescent team sports.

Journal of science and medicine in sport·2006

Same author

Treatment of acute lower limb ischemia following the use of the Duett sealing device: report of three cases and review of the literature.

Cardiovascular and interventional radiology·2004

Same author

Effects of delayed (24 h postintervention) beta-irradiation therapy after coronary angioplasty and stenting in de novo native coronary artery lesions; Results of a randomized clinical and intravascular ultrasound study.

Cardiovascular radiation medicine·2004

Search research articles

Related Experiment Video

Updated: Jul 24, 2026

Electrode Positioning and Montage in Transcranial Direct Current Stimulation

Electrode Positioning and Montage in Transcranial Direct Current Stimulation

Published on: May 23, 2011

Direct current shock and antidysrhythmic drugs.

P Szekely, N A Wynne, D T Pearson

British Heart Journal

|March 1, 1970

Summary

Combining antiarrhythmic drugs with direct current (DC) shock therapy for atrial fibrillation improves conversion rates. However, caution is advised as these drug combinations may increase cardiotoxicity and post-shock rhythm disorders.

Area of Science:

Cardiology
Clinical Electrophysiology

Background:

Atrial fibrillation (AF) is a common arrhythmia requiring treatment.
Direct current (DC) shock is a primary method for AF cardioversion.
The role of antiarrhythmic drugs in conjunction with DC shock requires further investigation.

Purpose of the Study:

To evaluate the efficacy and safety of combining antiarrhythmic drugs with DC shock for AF treatment.
To compare the effectiveness of DC shock alone versus combined therapy.
To assess the impact of specific drug combinations on DC shock outcomes.

Main Methods:

Review of 457 AF episodes in 318 patients treated with DC shock.
Concomitant use of antiarrhythmic drugs (quinidine, procainamide, propranolol) in 389 instances.

More Related Videos

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Published on: June 7, 2016

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Related Experiment Videos

Last Updated: Jul 24, 2026

Electrode Positioning and Montage in Transcranial Direct Current Stimulation

Electrode Positioning and Montage in Transcranial Direct Current Stimulation

Published on: May 23, 2011

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Published on: June 7, 2016

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Animal experiments studying combined quinidine/procainamide and DC shock effects.

Main Results:

Combined drug and DC shock therapy yielded higher conversion rates than DC shock alone.
Procainamide and propranolol combination showed a statistically significant improvement (p<0.01).
Antiarrhythmic drugs did not generally reduce DC shock-induced dysrhythmias, but propranolol/procainamide pretreatment lessened certain digitalis/DC shock-induced arrhythmias (p<0.01).

Conclusions:

Combined antiarrhythmic drug and DC shock therapy enhances AF cardioversion.
Caution is necessary due to potential enhanced cardiotoxicity and drug-related post-shock rhythm disorders.
Specific drug combinations may mitigate certain adverse events, but overall safety requires careful consideration.